Dual-energy x-ray absorptiometry firms Lunar and Hologic are gettinga boost from pharmaceutical giant Merck, which signed separatejoint financing agreements with the densitometry competitors topromote sales of their DEXA scanners in the U.S. Merck, of
Dual-energy x-ray absorptiometry firms Lunar and Hologic are gettinga boost from pharmaceutical giant Merck, which signed separatejoint financing agreements with the densitometry competitors topromote sales of their DEXA scanners in the U.S.
Merck, of West Point, PA, has developed Fosamax, a drug for thetreatment of osteoporosis that is close to receiving Food andDrug Administration approval. Merck hopes that the diffusion ofDEXA scanners will help fuel Fosamax sales when the drug becomesavailable. Merck estimates that there are 700 DEXA systems inclinical use in the U.S.
Under the agreements announced last week, Merck will assist infinancing the acquisition of DEXA scanners and will provide educationalprograms to increase awareness of bone mineral density testing.In Lunar's case, physicians will be able to acquire the Madison,WI, company's low-cost DPX densitometer on a fee-per-patient basis.Lunar's premium Expert system and its Achilles ultrasound productare not covered by the program.
Hologic will also provide its Acclaim fanbeam scanner on a fee-per-patientbasis, which reduces the initial investment needed to acquirecapital equipment. Physicians can withdraw from the program andreturn the equipment without penalty if there is no demand forDEXA services, Hologic said.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.